

Transforming patients' lives through science™



Our Mission

To discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

Our Vision

To be the leading pharmaceutical company in Switzerland that transforms patients' lives through science.

Bristol Myers Squibb in Switzerland

1,220 employees at five different locations, including three production facilities, make us one of the top five pharmaceutical companies in Switzerland.


Boudry
Pharmaceutical company and global functions
830 employees including apprentices

Couvet
Production facility
110 employees including apprentices

Steinhausen
Swiss branch, CHAT functions & Global Capabilities Hub
213 employees

Zofingen
Production facility
27 employees

Zurich
Swiss branch & CHAT functions
40 employees



Professionals incl.:
Administration
Biostatisticians
Chemists
Pharmacists
Physicians

Functions:
Corporate Affairs
Drug Safety
Finance
Human Resources
Information Technology
Legal & Compliance
Manufacturing
Market Access & Gov. Affairs
Marketing
Medical Affairs
Quality Assurance
Regulatory
Supply Chain
Strategy & Operations



99% of finished goods produced in Boudry and Couvet are exported to 80 countries.



We drive collaborative and constructive partnerships and open dialogue among stakeholders to create a healthcare system that provides patients with innovative medicines in a sustainable way.



Our ambition is to be one of the best employers in Switzerland. Ranking 4th in the "Great Place To Work" survey proves that we are taking this seriously.



Research and Development

We are the leader in conducting clinical trials in Switzerland, ensuring patients get early access to innovative medicines in the fight against cancer, the second leading cause of mortality.

We have one of the most diverse and promising pipelines in the industry fueled by research in oncology, hematology, immunology, and cardiovascular diseases.

60 clinical studies together with Cantonal and University Hospitals in Switzerland in 2020*

50+ Investigational therapies globally in the areas of:

Oncology

Immunology

Hematology

Fibrotic Diseases

Cardiovascular

Neuroscience

Leading Franchises

#1
Oncology & Hematology

#1
Cardiovascular

Growing Immunology Franchise

Deep and Broad Late-Stage Pipeline

8
Near-term potential launches

9
Phase III assets

20+
Life cycle management opportunities in IO

Robust Early-Stage Pipeline Phase I/II Assets

19
Oncology

15
Hematology

5
Cardiovascular

9
Immunology

5
Fibrosis

* as of 09/23/2020; source: clinicaltrials.gov